Literature DB >> 31162312

Highly Aggressive Multiple Sclerosis.

James D Bowen.   

Abstract

PURPOSE OF REVIEW: Newly introduced disease-modifying therapies offer greater efficacy than previous therapies but also have serious side effects. This article reviews factors useful in identifying those at risk of developing aggressive relapsing multiple sclerosis (MS) and therapies available for treatment. RECENT
FINDINGS: Several factors predict aggressive MS, including demographic factors, relapses, symptom characteristics, MRI activity, and other biomarkers. These can be used to select patients for more aggressive therapies, including natalizumab, alemtuzumab, fingolimod, and ocrelizumab. Additional off-label treatments are available for patients with severe disease. The benefits and side effects of these treatments must be considered when making therapeutic decisions.
SUMMARY: Selecting patients who are most appropriate for aggressive therapy involves considering risk factors for poor outcomes, early recognition of treatment failure, balancing treatment efficacy and side effects, and sharing the decision with patients to assist them in making optimal treatment choices. Vigilance for signs of treatment failure and early switching to more aggressive therapy are important components in optimal care.

Entities:  

Year:  2019        PMID: 31162312     DOI: 10.1212/CON.0000000000000731

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  2 in total

1.  Multiple sclerosis.

Authors:  Shilpa Klocke; Nicole Hahn
Journal:  Ment Health Clin       Date:  2019-11-27

Review 2.  Predictive MRI Biomarkers in MS-A Critical Review.

Authors:  Vlad Eugen Tiu; Iulian Enache; Cristina Aura Panea; Cristina Tiu; Bogdan Ovidiu Popescu
Journal:  Medicina (Kaunas)       Date:  2022-03-03       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.